Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challenges DUBLIN, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of combined findings from a social media analysis and a survey of people with narcolepsy... Read More

DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20 at 7:30 a.m. GMT / 2:30 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will... Read More

Generated $50.0 million in net revenue from sales of LUMRYZ™ 2,300 patients on LUMRYZ as of September 30 th , including 700 patients that initiated therapy in the quarter Received FDA approval for LUMRYZ for the treatment of cataplexy or EDS in patients 7 years and older with narcolepsy, granted ODE through October 16, 2031 LUMRYZ approval upheld by court in suit brought by Jazz regarding FDA’s determination that LUMRYZ is... Read More

DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, November 12, 2024, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2024. To access the... Read More

DUBLIN, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that yesterday, the U.S. District Court for the District of Columbia (“Court”) ruled in favor of the Food and Drug Administration (“FDA”) in a suit brought by Jazz Pharmaceuticals Inc. (“Jazz”) under the Administrative Procedure Act regarding the... Read More

DUBLIN, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, and nference , a health tech company dedicated to making biomedical data computable, today announced the publication of real-world data that identified the demographic characteristics and the top 20 most prevalent comorbidities of people living with narcolepsy.... Read More

LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy Granted Orphan Drug Exclusivity in pediatric narcolepsy patients 7 years and older through October 16, 2031 DUBLIN, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to... Read More

Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent Baseline data underscore that alerting agents alone are often insufficient for excessive daytime sleepiness DUBLIN, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines... Read More

Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens 91% reported being better able to sleep through the night after switching to LUMRYZ 93% of those who switched to LUMRYZ would recommend it to family or friends living with narcolepsy DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company... Read More

DUBLIN, Ireland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: 2024 Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 4 at 3:45 p.m. ET. Morgan Stanley 22 nd Annual Global Healthcare... Read More

DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of results of a post-hoc analysis from the completed pivotal Phase 3 REST-ON clinical trial demonstrating greater weight loss in patients who received LUMRYZ compared with placebo. The paper, titled “Weight Loss With Once-nightly... Read More

Generated $41.5 million in net revenue from sales of LUMRYZ™ More than 1,900 patients on LUMRYZ as of June 30 th First patient dosed in Phase 3 trial evaluating LUMRYZ in idiopathic hypersomnia FDA target action date of September 7, 2024 for sNDA for LUMRYZ in pediatric narcolepsy Management to host a conference call today at 8:30 a.m. ET DUBLIN, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a... Read More

DUBLIN, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 8, 2024, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2024. A live audio webcast of the... Read More

DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the first patient has been dosed in REVITALYZ, a Phase 3 study evaluating LUMRYZ as a potential treatment for idiopathic hypersomnia (IH). "IH is a debilitating sleep disorder characterized by profound sleep inertia, or difficulty waking up... Read More

DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions... Read More

DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 6 at 10:30 a.m. ET. Goldman Sachs 45 th Annual Global Healthcare Conference:... Read More

11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting... Read More

DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer... Read More

Generated $27.2 million in net revenue from sales of LUMRYZ™ Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients initiated therapy Pursuing expansion opportunities for LUMRYZ with sNDA in pediatric narcolepsy; on track to enroll first patient in a Phase 3 pivotal idiopathic hypersomnia trial in the second half of 2024 Management to host a conference... Read More

DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. To access the... Read More

DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 23 rd Annual Needham Healthcare Conference on Monday, April 8 at 10:15 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be... Read More

DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Leerink Global Biopharma Conference: Fireside chat on Monday, March 11 at 3:20 p.m. ET. UBS Virtual CNS Day: Fireside chat on Monday, March 18... Read More

DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware (“Court”) in a patent suit brought by Jazz Pharmaceuticals Inc. regarding LUMRYZ™. Avadel is pleased with the jury’s decision ruling in favor of Avadel with respect to one of the contested patents. As it relates... Read More

Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ As of January 31 st , greater than 2,200 patients enrolled in RYZUP TM and more than 1,200 patients initiated therapy Payer coverage now in place for greater than 80% of commercially covered lives for LUMRYZ through new listings including United Healthcare and Anthem FDA target action date of September 7, 2024,... Read More

DUBLIN, Ireland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 7:30 a.m. ET on Monday, March 4, 2024, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2023.... Read More

DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Oppenheimer 34 th Annual Healthcare Life Sciences Conference on Wednesday, February 14 at 2:00 p.m. ET. A live webcast of the fireside chat, as well as an archived... Read More

Approximately $19 million and $28 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter and full year 2023, respectively Generated continued robust demand for LUMRYZ with greater than 1,900 patients enrolled in RYZUP TM and more than 1,000 patients initiating therapy through December 31 Signed Emisar (Optum Rx GPO) contract, all 3 PBM owned GPO contracts now finalized for 2024 Supplemental New Drug... Read More

$7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUP TM and more than 400 patients initiating therapy as of September 30 LUMRYZ to be added to preferred position for CVS commercial formularies effective January 1, 2024 Submitted sNDA for LUMRYZ in pediatric narcolepsy population on November 7 th Management to host a... Read More

DUBLIN, Ireland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference: Fireside chat on Tuesday, November 14 at 5:00 p.m. GMT / 12:00 p.m. ET. Piper Sandler 35 th Annual... Read More

DUBLIN, Ireland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 8, 2023, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2023. A live audio... Read More

17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment option Company to host symposium on October 24 with leading KOLs discussing evolution of the narcolepsy treatment landscape DUBLIN, Ireland, Oct. 20, 2023 (GLOBE NEWSWIRE) - - Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform... Read More

DUBLIN, Ireland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Biotech CNS/Neuro Summit on Thursday, October 12 at 9:00 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available... Read More

DUBLIN, Ireland, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference: Fireside chat on Thursday, September 7 at 4:30 p.m. ET. H.C. Wainwright 25 th Annual Global Investment... Read More

Successfully commenced U.S. commercial launch of LUMRYZ™ Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through May 1, 2030 Significant early progress on payor coverage, prescriber certifications and patient enrollments Management to host a conference call today at 8:30 a.m. ET DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical... Read More

DUBLIN, Ireland, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three (3) new employees to purchase an aggregate of 26,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an... Read More

DUBLIN, Ireland, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 9, 2023, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2023. A live audio... Read More

DUBLIN, Ireland, July 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three (3) new employees to purchase an aggregate of 20,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an... Read More

DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase an aggregate of 90,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an... Read More

DUBLIN, Ireland, June 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a Commercial Day presentation to provide an overview of its commercial strategy for recently launched LUMRYZ on Thursday, June 29, 2023 beginning at 8:00 a.m. ET. LUMRYZ was approved by the U.S. Food & Drug... Read More

DUBLIN, Ireland, June 14, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced leader sponsorship of the American Academy of Sleep Medicine (AASM) Foundation’s 15 th Annual Young Investigators Research Forum (YIRF). This will be Avadel’s third year as lead sponsor of the YIRF program, which takes place March-June 2023, with virtual... Read More

DUBLIN, Ireland, June 13, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the publication of survey data describing clinician preferences among oxybate treatments for patients living with narcolepsy. The paper, titled “Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment,” was... Read More

DUBLIN, Ireland, June 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to fifteen (15) new employees to purchase an aggregate of 129,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted on... Read More

LUMRYZ is the first and only once-at-bedtime oxybate for people living with narcolepsy Once-nightly dosing regimen of LUMRYZ has been found by FDA to provide a major contribution to patient care over all twice-nightly oxybates DUBLIN, Ireland, June 05, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that... Read More

DUBLIN, Ireland, June 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8 at 1:00 p.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on... Read More

12 accepted abstracts highlight Company’s emerging leadership in narcolepsy Data adds to growing body of evidence demonstrating positive clinical benefit and patient preference of once-at-bedtime LUMRYZ Company to support symposium on June 6 with leading KOLs discussing unmet needs in the advancement of narcolepsy treatment DUBLIN, May 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused... Read More

Received FDA approval for LUMRYZ™ (sodium oxybate), the first and only once-at-bedtime oxybate for treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy FDA awarded LUMRYZ Orphan Drug Exclusivity through May 1, 2030 LUMRYZ product availability on track for early June; robust market research and physician feedback supports potential of LUMRYZ to capture a meaningful share of the $3 billion... Read More

DUBLIN, May 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to twenty one (21) new employees to purchase an aggregate of 193,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an... Read More

Granted Orphan Drug Exclusivity through May 1, 2030 Advanced commercial preparations on track; LUMRYZ product availability expected in early June Final approval supported by robust efficacy and safety data from pivotal Phase 3 REST-ON clinical trial Management to host conference call today, May 1, 2023 at 4:00 p.m. ET DUBLIN, May 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical... Read More

DUBLIN, Ireland, April 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to thirty two (32) new employees to purchase an aggregate of 236,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted... Read More

DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference on Monday, April 17 at 9:30 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be... Read More

DUBLIN, April 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three (3) new employees to purchase an aggregate of 46,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement... Read More

LUMRYZ™ NDA amendment filed March 1 requesting FDA final approval Received FDA authorization to import LUMRYZ in advance of final approval decision; shortens timeline between potential approval and product availability Secured $200 million of capital to fund the launch of LUMRYZ and extended the maturity of $96.2 million of the convertible notes to 2027 Launch preparations on track to support U.S. commercial launch of LUMRYZ... Read More

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 30, 2023, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2022. A... Read More

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the pricing of an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per share (“Ordinary Shares”) in the form of American Depositary Shares (“ADSs”) and of 4,705,882 Series B Non-Voting... Read More

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is commencing an underwritten public offering of its ordinary shares, nominal value $0.01 per share (“Ordinary Shares”) in the form of American Depositary Shares (“ADSs”). Each ADS represents the right to receive one... Read More

In parallel, extended maturity on $96.2 million of convertible notes to April 1, 2027 Strategic financings strengthen the company’s balance sheet in advance of potential commercialization of LUMRYZ DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its entry into a royalty agreement... Read More

DUBLIN, Ireland, March 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its Pre-Launch Activities Importation Requests (PLAIR) for LUMRYZ. Through its PLAIR, Avadel is authorized to import unapproved drug product into the U.S. ahead of... Read More

DUBLIN, Ireland, March 21, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to one (1) new employee to purchase 15,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material... Read More

Submitted amendment on March 1, 2023 to the LUMRYZ NDA seeking final FDA approval DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it has submitted an amendment to the U.S. Food and Drug Administration (“FDA”) requesting final approval for LUMRYZ for the treatment of cataplexy... Read More

DUBLIN, Ireland, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two (2) new employees to purchase an aggregate of 28,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an... Read More

DUBLIN, Ireland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15 at 1:00 p.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be... Read More

DUBLIN, Ireland, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two (2) new employees to purchase an aggregate of 38,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an... Read More

Adverse events were reported in patients who took the second, middle-of-the-night dose of immediate-release oxybate less than 2.5 hours after the first dose DUBLIN, Ireland, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of real-world data describing the risk of accidental dosing... Read More

DUBLIN, Ireland, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three (3) new employees to purchase an aggregate of 40,500 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an... Read More

DUBLIN, Ireland, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to six (6) new employees to purchase an aggregate of 105,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an... Read More

DUBLIN, Ireland, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three (3) new employees to purchase an aggregate of 42,500 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an... Read More